Specifically, we included 18 heterozygous carriers of the LRRK2 G2019S mutation (11 PD/7 non-manifesting carriers (NMC)), 13 with LRRK2 R1441G/C (7 PD/6 NMC) and 10 with the pathogenic VPS35 D620N mutation (9 PD/1 NMC), as well as 10 individuals with PD associated with various GBA risk variants. This evidence concerns the gene LRRK2 and Parkinson disease.